Blocking type pd-l1 single-domain camel antibody and application thereof
AssigneeShanghai Novamab Biopharmaceuticals Co., Ltd.
InventorsYakun WAN, Min ZHU, Xiaoning SHEN, Junwei GAI
Life of this patent
Estimating the term…
Abstract
Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.
Claims17
1-18. (canceled)
An anti-PD-L1 single-domain antibody, which is a single-domain antibody targeting PD-L1 epitope and has a VHH chain having the following 3 complementarity determining regions or CDRs:
- CDR1 as shown in SEQ ID No:
- 5, CDR2 as shown in SEQ ID No:
- 6, and CDR3 as shown in SEQ ID No:
- 7.
A polynucleotide which encodes an anti-PD-L1 single-domain antibody of claim 1.
A host cell whose genome has been incorporated a polynucleotide that encodes an anti-PD-L1 single-domain antibody of claim 1 or which contains an expression vector containing the polynucleotide.
Dependencies are inferred from the claim text.